Document is current
Any future updates will be listed below
-
Authors
Chen, Yingjia
He, Liye https://orcid.org/0000-0002-6632-2112
Ianevski, Aleksandr
Ayuda-Durán, Pilar https://orcid.org/0000-0002-9799-3680
Potdar, Swapnil
Saarela, Jani https://orcid.org/0000-0001-7306-7175
Miettinen, Juho J. https://orcid.org/0000-0002-3987-1693
Kytölä, Sari
Miettinen, Susanna https://orcid.org/0000-0002-0647-9556
Manninen, Mikko
Heckman, Caroline A.
Enserink, Jorrit M.
Wennerberg, Krister
Aittokallio, Tero https://orcid.org/0000-0002-0886-9769
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (101057442)
Academy of Finland (310507, 313267, 313267, 326238, 340141, 344698, 345803, 336666, 326588, 312413, 353177, 320185, 334781)
Ministry of Health and Care Services | Helse Sør-Øst RHF (2020026, 2017064, 2018012, 2019096)
CSC | Distinguished International Students Scholarship
NordForsk (96782)
Kreftforeningen (182524, 208012)
Norges Forskningsråd (262652)
- License Information
-
More Information
Article History
Received: 24 March 2023
Accepted: 10 August 2023
First Online: 23 November 2023
Competing interests
: S.M. receives research funding from Oncopeptides for work unrelated to the present study. C.A.H. receives research funding from Kronos Bio, Novartis, Oncopeptides, WNTResearch and Zentalis Pharmaceuticals for work unrelated to the present study and honoraria from Amgen. T.A. receives research funding from the European Union’s Horizon Europe Research & Innovation programme under grant agreement no. 101057442. The views and opinions expressed in this document are those of the authors only. They do not necessarily reflect those of the European Union who cannot be held responsible for the information it contains. All the other authors declare no competing interests.
